• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 1, 2013

View Archived Issues

AC Immune Drops ACI-91 on Phase II Alzheimer's Failure

The drug development graveyard that is Alzheimer's disease has claimed yet another victim. This time it's AC Immune SA's ACI-91, a drug that had offered a new approach to tackling this most intractable of diseases. Read More

Early Phase III Data Hint at Rituxan Replacement

Genentech Inc., a unit of the Roche Group, could add another agent to its formidable oncology arsenal if initial findings from a Phase III study of lead hematology candidate GA101 (obinutuzumab) are borne out in a three-arm trial. Read More

'Iron Still Hot,' as FDA Vague on Off-Label Speech Freedom

Late last year, when federal appeals judges threw out the conviction of a former pharma sales rep for off-label marketing after the rep argued that prosecuting him had violated his freedom of speech, the industry could not be sure what it meant for the rest of them. Read More

Antibody Firm KaloBios Prices $70M IPO in Lukewarm Debut

In the second biotech initial public offering (IPO) to price this week, antibody drug developer KaloBios Pharmaceuticals Inc. priced a slightly upsized offering of 8.75 million shares at $8 apiece for gross proceeds of $70 million. Like Stemline Therapeutics Inc., which priced an IPO Tuesday, KaloBios came in at the low end of its expected pricing range. Read More

Earnings Roundup

• Alkermes plc, of Dublin, Ireland, reported net income of $46.5 million, or 34 cents per share, for the three months ending Dec. 31 – the firm's third fiscal quarter – which solidly beat analyst estimates of 26 cents per share. Read More

Other News To Note

• Dyax Corp., of Burlington, Mass., and Novellus Biopharma AG, of Bogota, Colombia, inked a partnership for the development and commercialization of hereditary angioedema drug Kalbitor (ecallantide) in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. Read More

Stock Movers

Read More

Clinic Roundup

• Arteriocyte Inc., of Cleveland, said it received FDA approval to start a Phase I trial testing its Magellan System technology in the treatment of thermal burn wounds. Read More

Pharma: Other News To Note

• Pfizer Inc., of New York, said the District Court of Delaware ruled that its patent covering a method for using sirolimus, the active ingredient in Rapamune, for the inhibition of organ transplant rejection is valid and infringed. Read More

Appointments and Advancements

• Cubist Pharmaceuticals Inc., of Lexington, Mass., appointed Thomas J. DesRosier senior vice president, chief legal officer and secretary. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 11, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 8, 2025
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Incurix describes new c-Myc inhibitors

    BioWorld Science
    Incurix Co. Ltd. has identified Myc proto-oncogene protein (c-Myc) inhibitors reported to be useful for the treatment of cancer.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe